Surprise Q1 Loss Sends Hims & Hers Down 16% as Branded Weight-Loss Drug Pivot Hits Margins
HIMS sits 79% above its 52-week low of $13.74.
Summary
Hims & Hers Health reported a surprise first-quarter loss of 40 cents per share, significantly missing analyst expectations of a 4-cent profit, causing its stock to plunge 16% premarket. This follows the company's 8-K and 10-Q filings on May 11th, which disclosed a Q1 net loss and lower Adjusted EBITDA. The negative results are primarily attributed to a strategic pivot from cheaper, compounded GLP-1 drugs to more expensive branded versions, which drove up costs, pressured margins, and led to restructuring charges and write-downs. The company, which competes with branded drug makers like Eli Lilly (LLY), expects to return to profit in 2027, but analysts view this target as aspirational. Investors will closely monitor the execution of this strategic shift and its impact on future profitability and market share.
At the time of this announcement, HIMS was trading at $24.62 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $13.74 to $70.43. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.